Foresite Capital Management III, LLC Buys Ascendis Pharma A/S, Natera Inc, Sells Aclaris Therapeutics Inc, , Epizyme Inc

Feb 18, 2022

Investment company Foresite Capital Management III, LLC (Current Portfolio) buys Ascendis Pharma A/S, Natera Inc, sells Aclaris Therapeutics Inc, , Epizyme Inc, Novavax Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Foresite Capital Management III, LLC. As of 2021Q4, Foresite Capital Management III, LLC owns 4 stocks with a total value of $40 million. These are the details of the buys and sells.

New Purchases: ASND, NTRA,
Sold Out: ACRS, XLRN, EPZM, NVAX,

For the details of Foresite Capital Management III, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/foresite+capital+management+iii%2C+llc/current-portfolio/portfolio

These are the top 5 holdings of Foresite Capital Management III, LLC

Ascendis Pharma A/S (ASND) - 133,691 shares, 45.53% of the total portfolio. New Position
Natera Inc (NTRA) - 91,000 shares, 21.51% of the total portfolio. New Position
Verona Pharma PLC (VRNA) - 1,111,112 shares, 18.90% of the total portfolio.
CymaBay Therapeutics Inc (CBAY) - 1,641,804 shares, 14.05% of the total portfolio.
Novavax Inc (NVAX) - 0 shares, 0.00% of the total portfolio. Shares reduced by 10000%

New Purchase: Ascendis Pharma A/S (ASND)

Foresite Capital Management III, LLC initiated holding in Ascendis Pharma A/S. The purchase prices were between $127.1 and $169.66, with an estimated average price of $148.37. The stock is now traded at around $112.860000. The impact to a portfolio due to this purchase was 45.53%. The holding were 133,691 shares as of 2021-12-31.

New Purchase: Natera Inc (NTRA)

Foresite Capital Management III, LLC initiated holding in Natera Inc. The purchase prices were between $86.26 and $119, with an estimated average price of $103.38. The stock is now traded at around $64.080000. The impact to a portfolio due to this purchase was 21.51%. The holding were 91,000 shares as of 2021-12-31.

Sold Out: Aclaris Therapeutics Inc (ACRS)

Foresite Capital Management III, LLC sold out a holding in Aclaris Therapeutics Inc. The sale prices were between $12.27 and $18.49, with an estimated average price of $15.09.

Sold Out: (XLRN)

Foresite Capital Management III, LLC sold out a holding in . The sale prices were between $172.08 and $179.68, with an estimated average price of $174.41.

Sold Out: Epizyme Inc (EPZM)

Foresite Capital Management III, LLC sold out a holding in Epizyme Inc. The sale prices were between $2.5 and $5.05, with an estimated average price of $3.89.

Sold Out: Novavax Inc (NVAX)

Foresite Capital Management III, LLC sold out a holding in Novavax Inc. The sale prices were between $134.56 and $217.97, with an estimated average price of $172.19.

Here is the complete portfolio of Foresite Capital Management III, LLC. Also check out:

1. Foresite Capital Management III, LLC's Undervalued Stocks
2. Foresite Capital Management III, LLC's Top Growth Companies, and
3. Foresite Capital Management III, LLC's High Yield stocks
4. Stocks that Foresite Capital Management III, LLC keeps buying

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.